Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy
- 28 February 2009
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 19 (1), 17-24
- https://doi.org/10.1016/j.semcancer.2008.11.006
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancerBritish Journal of Cancer, 2008
- Causes and Consequences of Increased Glucose Metabolism of CancersJournal of Nuclear Medicine, 2008
- Hexokinase II Detachment from Mitochondria Triggers Apoptosis through the Permeability Transition Pore Independent of Voltage-Dependent Anion ChannelsPLOS ONE, 2008
- Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell deathNature, 2007
- Lactate and malignant tumors: A therapeutic target at the end stage of glycolysisJournal of Bioenergetics and Biomembranes, 2007
- METABOLIC REMODELING OF MALIGNANT GLIOMAS FOR ENHANCED SENSITIZATION DURING RADIOTHERAPYNeurosurgery, 2006
- Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaOncogene, 2006
- Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATPBiochemical and Biophysical Research Communications, 2004
- Glucose catabolism in cancer cells: regulation of the type II hexokinase promoter by glucose and cyclic AMPFEBS Letters, 1996
- Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatomaBiochemical and Biophysical Research Communications, 1985